

in the GLENN DECLARATION II is recognized in the art as a CAAX mimetic (See Rowinsky et al., *J. Clin. Oncol.*, 17:3631-3652 (1999 at page 3638))¹. FTI-2153, another compound described in the GLENN DECLARATION II, is also a CAAX mimetic (See Exhibit B at page 4920).

Applicant submits that the rejection of claims 13-21 under 35 U.S.C. §112 has been overcome by the above remarks and/or amendments. Early allowance of the pending claims 13, 14, 16 and 18-23 is earnestly requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 240042052403. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 3, 2002

By:


Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5147
Facsimile: (858) 720-5125

¹ The Rowinsky article was sent to the Examiner via facsimile on February 21, 2002.